Adjusted mean differences in HRQoL profile by the EORTC QLQ-C30 questionnaire between patients with APL previously treated with ATRA-ATO vs ATRA chemotherapy. The figure represents differences in mean scores and corresponding 95% CIs, adjusted for time since protocol completion, of functional and global QoL scales (A) and symptom scales (B) from the EORTC QLQ-C30 questionnaire between long-term APL survivors previously treated with ATRA plus arsenic trioxide or ATRA plus chemotherapy. For descriptive purposes, the mean difference scores and corresponding 95% CIs of the symptom scales were multiplied by −1. Positive differences in functional and symptom scales indicate better outcomes in the ATRA plus arsenic trioxide arm than in the ATRA plus chemotherapy arm. A red circle indicates a clinically relevant difference.